Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:05:24.947Z.
Calculation as of: 2026-10-06T18:05:24.947Z.
Quote observation: 2026-10-06T17:59:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$267.85M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$263.79M
Price/FCF Ratio
N/A
TTM Avg
61.29
3Y Avg
61.29
5Y Avg
61.29
Market Cap
$262.79M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$261.97M
Price/FCF Ratio
N/A
TTM Avg
4.69
3Y Avg
5.94
5Y Avg
441.51
Market Cap
$269.68M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$269.87M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$270.82M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Scribe Therapeutics Inc. (SCTX) | $267.33M | N/A | N/A | N/A | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $267.85M | N/A | N/A | N/A | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $263.79M | N/A | 61.29 | 61.29 | 61.29 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.79M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $261.97M | N/A | 4.69 | 5.94 | 441.51 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.68M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $261.15M | N/A | N/A | N/A | N/A |
| Treace Medical Concepts, Inc. (TMCI)vs › | $269.87M | N/A | N/A | N/A | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $270.82M | N/A | N/A | N/A | N/A |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $270.31M | N/A | 10.48 | 12.46 | 16.12 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
